Multicenter Cohort Study of AAV in Hunan of China

Status Recruiting

Clinical Trial Summary

This study aimed to explore the incidence of Anti-neutrophil cytoplasmic antibody (ANCA）-associated vasculitis (AAV) progression and its association with adverse consequences. It will enroll approximately 500 AAV patients in Hunan province of China and follow-up for at least 5 years. Demographic characteristics, clinical and laboratory data will be collected at baseline and every follow-up. The principal clinical outcomes of the study consist of end stage renal disease (ESRD) and death.

Clinical Trial Description

The study is a multicenter prospective cohort study, aimed to explore the incidence of AAV and its progression and association with adverse consequences. The study will establish a baseline cohort of 500 AAV patients in Hunan province of China. The follow-up will be conducted for at least 5 years until death or starting renal replacement therapy or dropout. Their demographic characteristics, clinical data, laboratory and imaging examinations will be collected at baseline and every follow-up. The baseline visit includes the following items: detailed demographics, medical and family history, medication history, health behaviors, physical activity, and anthropometric measures. The laboratory parameters of chemistry test. After the baseline visit, participants will return annually for follow-up visits and evaluation. The evaluating items of follow-up visits are similar to the baseline visit, and sample collection. The principal clinical outcomes of the study can be broadly categorized as end stage renal disease and death. Death is further clarified as cardiac, infectious, renal, others, or unknown. ;

Study Design

Related Conditions & MeSH terms

ANCA Associated Vasculitis
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Vasculitis

Clinical Trial Details

NCT number	NCT05315141
Study type	Observational [Patient Registry]
Source	Xiangya Hospital of Central South University
Contact	Yong Zhong, doctor
Phone	+86073189753025
Email	zhongyong121@163.com
Status	Recruiting
Phase
Start date	March 16, 2022
Completion date	March 16, 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06462768` - Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis
Recruiting	`NCT03942887` - Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis	Phase 3
Not yet recruiting	`NCT06420154` - The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases	Early Phase 1
Completed	`NCT04895878` - Patients With Co-occurrence of ANCA Vasculitis and Sjögren Syndrome
Completed	`NCT00293072` - Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis	Phase 2
Recruiting	`NCT04664465` - PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS
Terminated	`NCT05376319` - PR3-AAV Resilient Remission or PRRR	Phase 2
Recruiting	`NCT04737343` - Comparison of the Efficacy of Leflunomide and Azathioprine for the Maintenance Therapy of ANCA Associated Vasculitis	N/A
Recruiting	`NCT05962840` - Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)	Phase 4
Suspended	`NCT03906227` - Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive (CD5+) Regulatory B Cell Recovery in ANCA Vasculitis	N/A
Not yet recruiting	`NCT06152172` - CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101	Phase 1
Not yet recruiting	`NCT05946564` - A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial	Phase 3
Recruiting	`NCT04923074` - the Application of Diffusion Tensor Imaging in the Evaluation of Peripheral Neuropathy in ANCA Associated Vasculitis
Active, not recruiting	`NCT01633476` - CMV Modulation of the Immune System in ANCA-associated Vasculitis	Phase 2
Not yet recruiting	`NCT05416723` - Occupational and Environmental Origins of ANCA Vasculitis: Contribution of Data From the National Network for Vigilance and Prevention of Occupational Pathologies (RNV3P)
Recruiting	`NCT06277427` - Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells	N/A
Active, not recruiting	`NCT03967925` - Rituximab and Belimumab Combination Therapy in PR3 Vasculitis	Phase 2
Recruiting	`NCT05630612` - ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)	Phase 2
Recruiting	`NCT04316494` - Hydroxychloroquine in ANCA Vasculitis Evaluation	Phase 4
Recruiting	`NCT03698071` - Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis	N/A